As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial
A supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint results
These data will be presented at the NASH-TAG Conference on Friday January 6th, 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.